Lyell Immunopharma Inc. (LYEL)
0.51
0.03 (5.31%)
At close: Apr 02, 2025, 3:59 PM
0.49
-2.43%
After-hours: Apr 02, 2025, 05:27 PM EDT
5.31% (1D)
| Bid | 0.49 |
| Market Cap | 148.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.31 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | -1.35 |
| Analyst | Hold |
| Ask | 0.49 |
| Volume | 380,377 |
| Avg. Volume (20D) | 1,031,220 |
| Open | 0.48 |
| Previous Close | 0.48 |
| Day's Range | 0.48 - 0.51 |
| 52-Week Range | 0.48 - 3.15 |
| Beta | -0.42 |
About LYEL
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2021
Employees 300
Stock Exchange NASDAQ
Ticker Symbol LYEL
Website https://www.lyell.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LYEL stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 97.32% from the latest price.
Stock Forecasts4 months ago
+19.35%
Lyell Immunopharma shares are trading higher. The ...
Unlock content with
Pro Subscription
5 months ago
-5.22%
Lyell Immunopharma shares are trading higher after the company announced it will acquire privately-owned clinical-stage biotechnology company ImmPACT Bio.
